MHRA opened an investigation into clinics promoting unregulated peptides
The MHRA began investigating UK clinics making therapeutic claims about unregulated peptide products. BPC-157 was reported as the first compound named. The regulator's stated position is that the products are unlicensed and the marketing has run ahead of the evidence.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.